by Osteogenesis imperfecta, commonly known as brittle bone disease, is a rare genetic disorder characterized by bones that break easily, often from little or no apparent cause. It can range from mild to severe forms. The current treatment options available for osteogenesis imperfecta include bisphosphonates, calcium and vitamin D supplements, physical therapy, braces, wheelchairs, and in severe cases, bone marrow/stem cell transplant. Gene therapies are emerging as a promising treatment approach for osteogenesis imperfecta. Vector-based gene therapies aim to deliver a healthy copy of the gene into the cells to correct the defective collagen production. A few gene therapy companies are conducting clinical trials to evaluate the efficacy and safety of their adeno-associated virus (AAV)-based gene therapies in treating osteogenesis imperfecta.
The global Osteogenesis Imperfecta Treatment Market is estimated to be valued at US$ 722.8 Mn in 2023 and is expected to exhibit a CAGR of 14% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The growing adoption of gene therapies for osteogenesis imperfecta treatment is expected to be a key driver for market growth over the forecast period. Gene therapies have potential to efficiently deliver functional genes directly into bone cells to restore collagen production and bone formation. Osteogenesis imperfecta gene therapy products in the pipeline have demonstrated positive initial clinical data, showing significant increase in bone mineral density and reductions in fracture incidence. This highlights the potential of gene therapies to emerge as a mainstay treatment for osteogenesis imperfecta. Increasing funding and investments to advance research in rare disease treatments including osteogenesis imperfecta will also support the market growth. Government support for orphan drug development along with regulatory incentives encourages industry players to develop new treatment options thus propelling market expansion.
Segment Analysis
The Osteogenesis Imperfecta Treatment market can be segmented based on type, treatment, and end user. By type, the market is segmented into type 1, type 2, type 3, and type 4. Type 1 dominates the market and accounts for around 50% share. This is due to its high prevalence rate and early onset of symptoms, which requires long term treatment.
By treatment, the market is segmented into bisphosphonates, calcium & vitamin D supplementation, bone building therapies, genetics therapy, and others. Bisphosphonates dominates with a share of over 30% as it is the first line standard treatment recommended for all types of OI.
By end user, the market is segmented into hospitals, clinics, research organizations, and others. Hospitals hold the largest share due to availability of advanced treatment facilities and skilled healthcare professionals for management of OI.
PEST Analysis
Political: Government initiatives to spread awareness about rare diseases and favorable regulations for orphan drug development are supporting market growth.
Economic: Rising healthcare spending and growing income levels in emerging markets are increasing access to advanced treatment options.
Social: Increasing incidence of OI and demand for improved standard of care are driving research into new therapies. Support groups are creating awareness.
Technological: Advances in genetics research and development of novel drugs are expected to transform treatment landscape over the forecast period. Companies are developing targeted therapies through stem cell research.
Key Takeaways
– The Global Osteogenesis Imperfecta Treatment Market Demand is expected to witness high growth. Regional analysis related content comprises Regional analysis related content
– North America dominates the market currently due to presence of major players and advanced healthcare infrastructure for management of rare diseases. Asia Pacific is expected to witness fastest growth over forecast period supported by growing medical tourism and increasing spending by regional markets like China and India.
– Key players operating in the Osteogenesis Imperfecta Treatment market are BioSenic SA, Mereo Biopharma Group PLC, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Amgen Inc., Sun Pharmaceutical Industries Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Jubilant Pharmova Limited, Aurobindo Pharma, Quince, Ultragenyx Pharmaceutical Inc. and OrthoPediatrics Corp. These players are focusing on developing novel therapeutics to diversify product portfolio and strengthen market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
